Skip to contentP
Pure Bioscience, Inc.
P
PUREPure Bioscience, Inc. Q1 2020 · 10-Q
Revenue$398.00K$398.00K−32.5% vs Q1 2019 Net Income-$1.13M-$1.13MN/M vs Q1 2019 EPS Diluted-$0.01-$0.01N/M vs Q1 2019 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pure Bioscience, Inc. · CIK 1006028 · Engraved from SEC EDGAR
Operating Cash Flow-$324,000N/M Margins · derivedGross margin60.8%
Operating margin-283.9%+150.5 pt vs Q1 2019
Net margin-282.7%+152.3 pt vs Q1 2019
ended Oct 31, 2019 · filed Dec 13, 2019 · 43 d after period end